Delavirdine Mesylate, a Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitor
- 1 January 1996
- book chapter
- Published by Springer Nature
- Vol. 394, 279-289
- https://doi.org/10.1007/978-1-4757-9209-6_25
Abstract
Delavirdine mesylate (U-90152, DLV) is a potent second generation non-nucleoside HIV-1 reverse transcriptase inhibitor (RTI) from a new class of bisheteroarylpiperizine (BHAP) compounds discovered at Upjohn Laboratories.1–5Keywords
This publication has 24 references indexed in Scilit:
- Combination Therapy with Zidovudine Prevents Selection of Human Immunodeficiency Virus Type 1 Variants Expressing High-Level Resistance to L-697,661, a Nonnucleoside Reverse Transcriptase InhibitorThe Journal of Infectious Diseases, 1995
- Phase I Study of Atevirdine, a Nonnucleoside Reverse Transcriptase Inhibitor, in Combination with Zidovudine for Human Immunodeficiency Virus Type 1 InfectionThe Journal of Infectious Diseases, 1995
- In Vitro Inhibition Of Human Immunodeficiency Virus Type 1 By A Combination Of Delavirdine (U-90152) With Protease Inhibitor U-75875 Or Interferon-The Journal of Infectious Diseases, 1995
- Application OF Branched DNA Signal Amplification to Monitor Human Immunodeficiency Virus Type 1 Burden in Human PlasmaThe Journal of Infectious Diseases, 1994
- Interactions Between Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse TranscriptaseJournal of General Virology, 1994
- Anti-human immunodeficiency virus type 1 activities of novel non-nucleoside reverse transcriptase inhibitorsJournal of Antimicrobial Chemotherapy, 1994
- A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse TranscriptaseNew England Journal of Medicine, 1993
- Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogs and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)carbonyl]-4-[3-[(1-methylethyl)amino]pyridinyl]piperazinemonomethanesulfonate (U-90152S), a second-generation clinical candidateJournal of Medicinal Chemistry, 1993